Investor Overview

Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

10 Years of Excellence

Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company.

Explore our journey

INVESTOR HIGHLIGHTS

Corporate Mission

Defining our Purpose

Investor Presentation

Explore our investor deck

Our Pipeline

Explore our pipeline

More News

Stock Quote

2024年 12月 21日 11:35 AM EST

Dec 21, 2024 11:35 AM EST

Volume
Day Low/High /
52 - Week Low/High /

2024年 12月 21日 11:35 AM EST

Dec 21, 2024 11:35 AM EST

Volume
Day Low/High /
52 - Week Low/High /

2024年 12月 21日 11:35 AM EST

Dec 21, 2024 11:35 AM EST

Volume
Day Low/High /
52 - Week Low/High /

2024年 12月 21日 11:35 AM EST

Dec 21, 2024 11:35 AM EST

Volume
Day Low/High /
52 - Week Low/High /

Minimum 15 minutes delayed.
Source: LSEG

Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).

Corporate Profile

10 Years of Excellence

INVESTOR HIGHLIGHTS

Corporate Mission

Investor Presentation

Our Pipeline

Event Calendar

Latest News

Stock Quote

Investor & Media Contacts